Skip to main content
Top
Published in:

Open Access 03-01-2024 | Cervical Cancer | Original Article

Competing risk nomogram and risk classification system for evaluating overall and cancer-specific survival in neuroendocrine carcinoma of the cervix: a population-based retrospective study

Authors: J. Liu, Y. Lyu, Y. He, J. Ge, W. Zou, S. Liu, H. Yang, J. Li, K. Jiang

Published in: Journal of Endocrinological Investigation | Issue 6/2024

Login to get access

Abstract

Objective

Neuroendocrine carcinoma of the cervix (NECC) is a rare malignancy with poor clinical prognosis due to limited therapeutic options. This study aimed to establish a risk-stratification score and nomogram models to predict prognosis in NECC patients.

Methods

Data on individuals diagnosed with NECC between 2000 and 2019 were retrieved from the Surveillance Epidemiology and End Results (SEER) database and then randomly classified into training and validation cohorts (7:3). Univariate and multivariate Cox regression analyses evaluated independent indicators of prognosis. Least absolute shrinkage and selection operator (LASSO) regression analysis further assisted in confirming candidate variables. Based on these factors, cancer-specific survival (CSS) and overall survival (OS) nomograms that predict survival over 1, 3, and 5 years were constructed. The receiver operating characteristic (ROC) curve, the concordance index (C-index), and the calibration curve estimated the precision and discriminability of the competing risk nomogram for both cohorts. Finally, we assessed the clinical value of the nomograms using decision curve analysis (DCA).

Results

Data from 2348 patients were obtained from the SEER database. Age, tumor stage, T stage, N stage, chemotherapy, radiotherapy, and surgery predicted OS. Additionally, histological type was another standalone indicator of CSS prognosis. For predicting CSS, the C-index was 0.751 (95% CI 0.731 ~ 0.770) and 0.740 (95% CI 0.710 ~ 0.770) for the training and validation cohorts, respectively. Furthermore, the C-index in OS prediction was 0.757 (95% CI 0.738 ~ 0.776) and 0.747 (95% CI 0.718 ~ 0.776) for both cohorts. The proposed model had an excellent discriminative ability. Good accuracy and discriminability were also demonstrated using the AUC and calibration curves. Additionally, DCA demonstrated the high clinical potential of the nomograms for CSS and OS prediction. We constructed a corresponding risk classification system using nomogram scores. For the whole cohort, the median CSS times for the low-, moderate-, and high-risk groups were 59.3, 19.5, and 7.4 months, respectively.

Conclusion

New competing risk nomograms and a risk classification system were successfully developed to predict the 1-, 3-, and 5-year CSS and OS of NECC patients. The models are internally accurate and reliable and may guide clinicians toward better clinical decisions and the development of personalized treatment plans.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gadducci A, Carinelli S, Aletti G (2017) Neuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists. Gynecol Oncol 144:637–646CrossRefPubMed Gadducci A, Carinelli S, Aletti G (2017) Neuroendrocrine tumors of the uterine cervix: A therapeutic challenge for gynecologic oncologists. Gynecol Oncol 144:637–646CrossRefPubMed
2.
go back to reference Lu J, Li Y, Wang J (2022) Small Cell (Neuroendocrine) Carcinoma of the Cervix: An Analysis for 19 Cases and Literature Review. Front Cell Infect Microbiol 12:916506CrossRefPubMedPubMedCentral Lu J, Li Y, Wang J (2022) Small Cell (Neuroendocrine) Carcinoma of the Cervix: An Analysis for 19 Cases and Literature Review. Front Cell Infect Microbiol 12:916506CrossRefPubMedPubMedCentral
3.
go back to reference Cohen JG, Kapp DS, Shin JY et al (2010) Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol 203:347.e1–6CrossRefPubMed Cohen JG, Kapp DS, Shin JY et al (2010) Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol 203:347.e1–6CrossRefPubMed
4.
go back to reference Stoler M, Bergeron C, Colgan TJ (2014) WHO classification of tumours of female reproductive organs. International Agency for Research on Cancer Lyon 169–189 Stoler M, Bergeron C, Colgan TJ (2014) WHO classification of tumours of female reproductive organs. International Agency for Research on Cancer Lyon 169–189
7.
8.
go back to reference Dongol S, Tai Y, Shao Y et al (2014) A retrospective clinicopathological analysis of small-cell carcinoma of the uterine cervix. Mol Clin Oncol 2:71–75CrossRefPubMed Dongol S, Tai Y, Shao Y et al (2014) A retrospective clinicopathological analysis of small-cell carcinoma of the uterine cervix. Mol Clin Oncol 2:71–75CrossRefPubMed
13.
14.
go back to reference Diamand R, Ploussard G, Roumiguié M et al (2021) External validation of a multiparametric magnetic resonance imaging-based nomogram for the prediction of extracapsular extension and seminal vesicle invasion in prostate cancer patients undergoing radical prostatectomy. Eur Urol 79:180–185CrossRefPubMed Diamand R, Ploussard G, Roumiguié M et al (2021) External validation of a multiparametric magnetic resonance imaging-based nomogram for the prediction of extracapsular extension and seminal vesicle invasion in prostate cancer patients undergoing radical prostatectomy. Eur Urol 79:180–185CrossRefPubMed
15.
go back to reference Semenkovich TR, Yan Y, Subramanian M et al (2021) A clinical nomogram for predicting node-positive disease in esophageal cancer. Ann Surg 273:e214–e221CrossRefPubMed Semenkovich TR, Yan Y, Subramanian M et al (2021) A clinical nomogram for predicting node-positive disease in esophageal cancer. Ann Surg 273:e214–e221CrossRefPubMed
18.
go back to reference Li Q, Yu J, Yi H, Lan Q (2022) Distant organ metastasis patterns and prognosis of neuroendocrine cervical carcinoma: a population-based retrospective study. Front Endocrinol (Lausanne) 13:924414CrossRefPubMed Li Q, Yu J, Yi H, Lan Q (2022) Distant organ metastasis patterns and prognosis of neuroendocrine cervical carcinoma: a population-based retrospective study. Front Endocrinol (Lausanne) 13:924414CrossRefPubMed
19.
go back to reference McCusker ME, Coté TR, Clegg LX, Tavassoli FJ (2003) Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. Gynecol Oncol 88:333–339CrossRefPubMed McCusker ME, Coté TR, Clegg LX, Tavassoli FJ (2003) Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. Gynecol Oncol 88:333–339CrossRefPubMed
20.
go back to reference Chan JK, Loizzi V, Burger RA et al (2003) Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. Cancer 97:568–574CrossRefPubMed Chan JK, Loizzi V, Burger RA et al (2003) Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. Cancer 97:568–574CrossRefPubMed
21.
go back to reference Zhou J, Yang H-Y, Wu S-G et al (2016) The local treatment modalities in FIGO stage I-II small-cell carcinoma of the cervix are determined by disease stage and lymph node status. Cancer Med 5:1108–1115CrossRefPubMedPubMedCentral Zhou J, Yang H-Y, Wu S-G et al (2016) The local treatment modalities in FIGO stage I-II small-cell carcinoma of the cervix are determined by disease stage and lymph node status. Cancer Med 5:1108–1115CrossRefPubMedPubMedCentral
22.
go back to reference Kawamura M, Koide Y, Murai T et al (2021) The importance of choosing the right strategy to treat small cell carcinoma of the cervix: a comparative analysis of treatments. BMC Cancer 21:1046CrossRefPubMedPubMedCentral Kawamura M, Koide Y, Murai T et al (2021) The importance of choosing the right strategy to treat small cell carcinoma of the cervix: a comparative analysis of treatments. BMC Cancer 21:1046CrossRefPubMedPubMedCentral
23.
go back to reference Huang L, Liao L-M, Liu A-W et al (2014) Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients. BMC Cancer 14:140CrossRefPubMedPubMedCentral Huang L, Liao L-M, Liu A-W et al (2014) Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients. BMC Cancer 14:140CrossRefPubMedPubMedCentral
24.
go back to reference Ishikawa M, Kasamatsu T, Tsuda H et al (2018) Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: a multi-center retrospective study. Gynecol Oncol 148:139–146CrossRefPubMed Ishikawa M, Kasamatsu T, Tsuda H et al (2018) Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: a multi-center retrospective study. Gynecol Oncol 148:139–146CrossRefPubMed
27.
go back to reference Patel SP, Othus M, Chae YK et al (2020) A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res 26:2290–2296CrossRefPubMedPubMedCentral Patel SP, Othus M, Chae YK et al (2020) A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res 26:2290–2296CrossRefPubMedPubMedCentral
28.
go back to reference Patel SP, Mayerson E, Chae YK et al (2021) A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. Cancer 127:3194–3201CrossRefPubMed Patel SP, Mayerson E, Chae YK et al (2021) A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. Cancer 127:3194–3201CrossRefPubMed
29.
go back to reference Al-Toubah T, Halfdanarson T, Gile J et al (2022) Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. ESMO Open 7:100364CrossRefPubMed Al-Toubah T, Halfdanarson T, Gile J et al (2022) Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. ESMO Open 7:100364CrossRefPubMed
30.
go back to reference Paterniti TA, Dorr K, Ullah A et al (2021) Complete Response to Combination Nivolumab and Ipilimumab in Recurrent Neuroendocrine Carcinoma of the Cervix. Obstet Gynecol 138:813–816CrossRefPubMed Paterniti TA, Dorr K, Ullah A et al (2021) Complete Response to Combination Nivolumab and Ipilimumab in Recurrent Neuroendocrine Carcinoma of the Cervix. Obstet Gynecol 138:813–816CrossRefPubMed
Metadata
Title
Competing risk nomogram and risk classification system for evaluating overall and cancer-specific survival in neuroendocrine carcinoma of the cervix: a population-based retrospective study
Authors
J. Liu
Y. Lyu
Y. He
J. Ge
W. Zou
S. Liu
H. Yang
J. Li
K. Jiang
Publication date
03-01-2024
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 6/2024
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-023-02261-7

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more